The Explorer Air II, SurgVision’s new imaging platform, addresses challenges in oncological surgery
SurgVision, a company developing solutions for fluorescence-guided surgical and interventional oncology, part of the Bracco Group, announces that it has garnered U.S. FDA 510(k) clearance for the Explorer Air II for use with Pafolacianine (CYTALUX, On Target Laboratories Inc) during intraoperative fluorescence imaging.
This is reportedly the first product based on SurgVision’s next-generation technology platform. According to the company, it is designed to achieve high sensitivity and imaging fidelity, meeting the needs of oncological intraoperative fluorescence imaging. The system allows real-time imaging during surgery and its prototype has been tested by academic centers for a variety of indications.
“We are very excited about this important milestone. Our goal is to make the Explorer Air II available to surgeons supporting them in their mission to fight cancer,” says Stefan Schorling, CEO of SurgVision.
The Explorer Air II has also received the European CE mark for the visual assessment of blood flow and tissue perfusion.
Currently, the identification of tumors during surgery or interventional endoscopy relies on visual inspection and palpation. Tumor tissue is sometimes difficult to distinguish from healthy tissue, experts say. Consequently, surgical resection of the tumor is often incomplete. This has medical as well as financial implications, impairing patient treatment outcomes.
According to SurgVision, their response is a development pipeline combining highly sensitive imaging solutions to visualize tumors during surgical or interventional procedures in real-time, enabling a sensitive and accurate detection of the tumor.
